Xeris Biopharma Holdings, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:XERS) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 323.06 M392.01 M334.69 M370.19 M383.53 M Total liabilities 352.68 M379 M353.99 M371.05 M369.84 M Total equity -29.61 M13.01 M-19.3 M-861 K13.69 M Total liabilities & shareholders' equities 323.06 M392.01 M334.69 M370.19 M383.53 M Total debt 217.01 M221.22 M218.63 M219.47 M220.34 M Net debt 217.01 M109.47 M159.34 M127.87 M109.29 M

News

Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Xeris Pharmaceuticals at Barclays: Strong Growth Fueled by RECORLEV

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say

Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates

Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance

Xeris Pharmaceuticals earnings beat by $0.04, revenue topped estimates

Xeris Pharmaceuticals faces earnings test as growth accelerates

Why Are Shares Of Xeris Biopharma Falling Friday? - Xeris Biopharma Holdings (NASDAQ:XERS)

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics